MET-Amplified Lung Cancer: A New Target for XALKORI?

GRACEcast by Howard (Jack) West, MD

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

Related Episodes

Continue listening to more episodes from GRACEcast.

Jul 31, 2014 - 04:36

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung canc...

Jul 29, 2014 - 01:55

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for...

Jul 27, 2014 - 05:28

The doctors discuss the circumstances under which small cell lung cancer patients should receive prophyla...

Jul 24, 2014 - 02:03

NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and,...

Jul 22, 2014 - 02:27

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lu...

Jul 20, 2014 - 04:40

Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer pa...

Jul 17, 2014 - 07:28

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab...

Jul 15, 2014 - 03:15

Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and h...